BriaCell Therapeutics Corp. Warrant (BCTXW)

• Market cap: $93.3K
• 1 day: 4.59%
• 5 days: 28.7%
• 1 month: 6.47%
• 3 months: -62.05%
• 6 months: -71.7%
• Year to date: -89.68%
• 1 year: -83.15%
• 5 years: -96.05%
• 10 years: -96.05%
• Sector: Healthcare
• Industry: Biotechnology

About: BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

Employees: 12

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

0.5% more ownership

Funds ownership: 5.11% [Q1] → 5.61% (+0.5%) [Q2]

0% more funds holding

Funds holding: 7 [Q1] → 7 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

15% less capital invested

Capital invested by funds: $15.1K [Q1] → $12.9K (-$2.29K) [Q2]